Objective
Aenitis Technologies develops innovative solutions for separating, sorting and filtration of cells in suspension based on patented acoustophoresis technologies (pheresis based on acoustic radiation forces influence on polydisperced suspension).
Aenitis’ first axis of development is an innovative blood fractionation medical device for the production of labile blood products (LBP). It will overtake limits of currently used centrifugation processes which have many adverse effects as platelet activation (mainly due to induced shear forces). Aenitis approach revolutionizes the sector as it permit in a secure and simple process to product LBP. It also avoids platelet activation as shear forces are very low in acoustophoresis process.
This innovative Acoustic Blood Cells Sorter (ABC-S) project is highly recognized and awarded. It will solves major healthcare issues in LBP preparation by developing an innovative instrument capable of fractionating blood in continuous, without contact or pressure and with very low shear forces, to produce from whole blood high quality LBP. It will include the development of a platelet concentrate quality then unequalled in the world with a potentially conservation time significantly increased. This medical device will be associated with a disposable medical device to the source of recurring revenue. Blood medical devices world market is estimate to $14 Billion with an average growth annual rate of 5.5%. Yearly, 108 million blood donations are processed worldwide, including over 300 million in Europe and 460 million in North America. Our technology will have major impact for all blood banks’ LBP production; inducing a new gold standard driven by Europe.
This proposal for the call H2020 SME Instrument Phase 1 “Supporting innovative SMEs in the healthcare biotechnology sector: Cell technologies in medical applications” will permit Aenitis to grow from a functional laboratory-scale prototype to preindustrial prototypes first steps.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health scienceshealth sciencespublic health
- medical and health sciencesmedical biotechnologycells technologies
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
77290 MITRY MORY
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.